Data as of 10:34am ET
| +0.0259 / +3.65%|
Palatin Technologies, Inc. is a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. Palatin's programs are based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. The melanocortin system is useful to treat a variety of conditions and diseases, including sexual dysfunction, obesity and related disorders, cachexia (wasting syndrome) and inflammation-related diseases. The natriuretic peptide receptor system is useful in treatment of acute asthma, heart failure, hypertension and other cardiovascular diseases. The company's primary product in development is bremelanotide for the treatment of female sexual dysfunction (FSD). It is also developing an inhalation formulation of PL-3994, an agonist peptide mimetic which binds to natriuretic peptide receptor A, for treatment of acute exacerbations of asthma. The company also has drug candidates or development programs for sexual dysfunction, including erectile dysfunction, pulmonary diseases, heart failure, obesity and inflammatory diseases. Palatin Technologies was by Carl Spana and John K. A. Prendergast founded in 1986 and is headquartered in Cranbury, NJ.
|John K. A. Prendergast||Chairman|
|Carl Spana||President, Chief Executive Officer & Director|
|Stephen T. Wills||COO, CFO, Secretary, Treasurer & Executive VP|
|Jeff D. Edelson||Chief Medical Officer|
|Stephen A. Slusher||Chief Legal Officer|